<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2904221999
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESOMEP 20 mg gastro-resistant tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESOMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        55.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SALUTAS PHARMA GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SALUTAS PHARMA GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Esomep 20 mg contains a medicine called esomeprazole. This belongs to a group of medicines called &lsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach produces.</p><p>&nbsp;</p><p>Esomep 20 mg is used to treat the following conditions:</p><p>&nbsp;</p><p><u>Adults</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &lsquo;<em>Helicobacter pylori&rsquo;</em>. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Esomep 20 mg can also be used to stop stomach ulcers from forming if you are taking NSAIDs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged treatment after prevention of rebleeding of ulcers with intravenous Esomep.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Adolescents aged 12 years and above</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Esomep </strong>20 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic </strong>to esomeprazole or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic </strong>to similar medicines with active substance names ending in &ndash;prazole (e.g. pantoprazole, lansoprazole, rabeprazole, omeprazole),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines containing the active substance <strong>nelfinavir</strong>, a medicine to treat HIV infection.</p><p>Do not take Esomep 20 mg if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Esomep 20 mg.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Esomep 20 mg:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are due to have a specific blood test (Chromogranin A)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had a skin reaction after treatment with a medicine similar to Esomep that reduces stomach acid.</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with Esomep. Remember to also mention any other ill-effects like pain in your joints.</p><p>&nbsp;</p><p>&nbsp;</p><p>Esomep 20 mg may hide the symptoms of other diseases. <strong>Therefore, if any of the following happen to you before you start taking Esomep </strong>20 mg<strong> </strong><strong>or while you are taking it, talk to your doctor straight away:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You lose a lot of weight for no reason and have problems swallowing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You get stomach pain or indigestion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You begin to vomit food or blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You pass black stools (blood-stained faeces).</p><p>&nbsp;</p><p>If you have been prescribed Esomep 20 mg &ldquo;on demand&rdquo; you should contact your doctor if your symptoms continue or change in character.</p><p>&nbsp;</p><p>Taking a proton pump inhibitor like Esomep 20 mg, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>&nbsp;</p><p><strong>Children</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>Esomep 20 mg is not recommended for children under 12 years of age, as insufficient data exists.</p><p>&nbsp;</p><p><strong>Other medicines and Esomep </strong>20 mg</p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. This is because Esomep 20 mg can affect the way some medicines work and some medicines can have an effect on Esomep 20 mg.</p><p>&nbsp;</p><p>&nbsp;</p><p>Do not take Esomep 20 mg if you are taking a medicine containing nelfinavir (used to treat HIV).</p><p>&nbsp;</p><p>The following medicines can influence or be influenced by Esomep 20 mg:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>atazanavir</strong>, a medicine to treat HIV infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ketoconazole, itraconazole</strong>, or <strong>voriconazole</strong>, medicines to treat fungal infections</p><p>If necessary, the doctor will adjust the Esomep 20 mg dose for patients treated continuously, and patients with severely reduced liver functions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>erlotinib </strong>(used to treat cancer).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that are metabolised by a specific enzyme such as</p><p>-&nbsp;&nbsp; <strong>diazepam</strong>, a sedative to calm and induce sleep</p><p>-&nbsp;&nbsp; <strong>citalopram</strong>, <strong>imipramine</strong>, <strong>clomipramine</strong>, medicines to treat depression</p><p>-&nbsp;&nbsp; <strong>phenytoin, </strong>a medicine to treat epilepsy and certain pain conditions</p><p>If necessary, your doctor must reduce the dose of these medicines, particularly during occasional use. If you take phenytoin, your doctor will monitor phenytoin levels in your blood, particularly when beginning or ending Esomep 20 mg treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>warfarin, phenprocoumon, acenocoumarol, </strong>medicines used to prevent normal blood clotting. Your doctor will monitor blood clotting values, particularly when beginning or ending Esomep 20 mg treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>cilostazol </strong>(used to treat intermittent claudication &ndash; a pain in your legs when you walk which is caused by an insufficient blood supply).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>cisapride, </strong>a medicine to treat stomach and bowel problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>methotrexate </strong>(a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are taking a high dose of methotrexate, your doctor may temporarily stop your Esomep 20 mg &nbsp;treatment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifampicin, </strong>an antibiotic (used for treatment of tuberculosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>St. John&rsquo;s wort</strong>, an herbal treatment for depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>digoxin, </strong>a medicine to treat different heart conditions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>clopidogrel, </strong>used to prevent atherothrombotic events (e.g. a heart attack or stroke)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>tacrolimus </strong>used to prevent rejection after organ transplantation.</p><p>&nbsp;</p><p>If your doctor has prescribed the antibiotics <strong>amoxicillin </strong>and <strong>clarithromycin </strong>as well as Esomep 20 mg to treat ulcers caused by <em>Helicobacter pylori </em>infection, it is very important that you tell your doctor about any other medicines you are taking.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pregnancy</strong></p><p>Your doctor will decide whether you can take Esomep 20 mg during this time.</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Breast-feeding</strong></p><p>It is not known if Esomep 20 mg passes into breast milk. Therefore, you should not take Esomep 20 mg if you are breastfeeding.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Esomep 20 mg is not likely to affect you being able to drive or use any tools or machines. However, side effects such as dizziness and blurred vision may uncommonly or rarely occur (see section 4). If affected, you should not drive or use machines.</p><p>&nbsp;</p><p><strong>Esomep </strong>20 mg<strong> </strong><strong>contains glucose and sucrose</strong></p><p>If you have been told by your doctor that you have an <strong>intolerance to some sugars</strong>, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Esomep 20 mg is not recommended for children less than 12 years old.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking this medicine for a long time, your doctor will want to monitor you (particularly if you are taking it for more than a year).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor has told you to take this medicine as and when you need it, tell your doctor if your signs of illness change.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will tell you how many tablets to take and how long to take them for. This will depend on your condition, how old you are and how well your liver works.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual doses are given below.</p><p>&nbsp;</p><p><u>Adults</u></p><p><strong>To treat heartburn caused by gastro-oesophageal reflux disease (GORD):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor has found that your food pipe (gullet) has been slightly damaged, the usual dose is two tablets once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your gullet has not yet healed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose once the gullet has healed is one Esomep 20 mg gastro-resistant tablet once a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your gullet has not been damaged, the usual dose is one Esomep 20 mg gastro- resistant tablet each day. Once the condition has been controlled, your doctor may tell you to take your medicine as and when you need it, up to a maximum of one Esomep 20 mg gastro-resistant tablet each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems, your doctor may give you a lower dose.</p><p>&nbsp;</p><p><strong>To treat ulcers caused by <em>Helicobacter pylori </em>infection and to stop them coming back:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is one Esomep 20 mg gastro-resistant tablet twice a day for one week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will also tell you to take antibiotics for example amoxicillin and clarithromycin.</p><p>&nbsp;</p><p><strong>To treat stomach ulcers caused by NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is one Esomep 20 mg gastro-resistant tablet once a day for 4 to 8 weeks.</p><p>&nbsp;</p><p><strong>To prevent stomach ulcers if you are taking NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is one Esomep 20 mg gastro-resistant tablet once a day.</p><p>&nbsp;</p><p><strong>To treat too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is two tablets twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will adjust the dose depending on your needs and will also decide how long you need to take the medicine for. The maximum dose is 80 mg twice a day.</p><p>&nbsp;</p><p><strong>Prolonged treatment after prevention of rebleeding of ulcers with intravenous Esomep:</strong></p><p>The usual dose is two tablets once a day for 4 weeks.</p><p>&nbsp;</p><p><u>Adolescents (12 years or older)</u></p><p><strong>To treat heartburn caused by gastro-oesophageal reflux disease (GORD):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor has found that your food pipe (gullet) has been slightly damaged, the usual dose is two &nbsp;tablets once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your gullet has not yet healed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose once the gullet has healed is one Esomep 20 mg gastro-resistant tablet once a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your gullet has not been damaged, the usual dose is one Esomep 20 mg gastro- resistant tablet each day. Once the condition has been controlled, your doctor may tell you to take your medicine as and when you need it, up to a maximum of one Esomep 20 mg gastro-resistant tablet each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems, your doctor may give you a lower dose.</p><p>&nbsp;</p><p><strong>To treat ulcers caused by <em>Helicobacter pylori </em>infection and to stop them coming back:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is one Esomep 20 mg gastro-resistant tablet twice a day for one week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will also tell you to take antibiotics for example amoxicillin and clarithromycin.</p><p>&nbsp;</p><p><strong>Taking this medicine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take your tablets at any time of the day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take your tablets with food or on an empty stomach.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow your tablets whole with a drink of water. Do not chew or crush the tablets. This is because the tablets contain coated pellets which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the pellets.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>What to do if you have trouble swallowing the tablets</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have trouble swallowing the tablets:</p><p>-&nbsp;&nbsp; Put them into a glass of still (non-fizzy) water. Do not use any other liquids.</p><p>-&nbsp;&nbsp; Stir until the tablets break up (the mixture will not be clear). Then drink the mixture straight away or within 15 minutes. Always stir the mixture just before drinking it.</p><p>-&nbsp;&nbsp; To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. The solid pieces contain the medicine - do not chew or crush them.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you cannot swallow at all, the tablet can be mixed with some water and put into a syringe. It can then be given to you through a tube directly into your stomach (&lsquo;gastric tube&rsquo;).</p><p>&nbsp;</p><p><strong>If you take more Esomep </strong>20 mg<strong> </strong><strong>than you should</strong></p><p>If you take more Esomep 20 mg than prescribed by your doctor, talk to your doctor or pharmacist straight away.</p><p>&nbsp;</p><p><strong>If you forget to take Esomep </strong>20 mg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you stop taking Esomep </strong>20 mg</p><p>Always take the prescribed dose for as long as your doctor prescribed. Interrupting or stopping treatment without your doctor&rsquo;s advice might reduce the success of your therapy.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>If you notice any of the following serious side effects, stop taking this medicine and contact a doctor immediately:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties in swallowing (severe allergic reaction) (rare: may affect up to 1 in 1,000 people).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reddening of the skin with blisters or peeling. There may also be severe blisters, bleeding in the lips, eyes, mouth, nose and genitals or high fever and joint pains. This could be &lsquo;Erythema multiforme&rsquo;, &lsquo;Stevens-Johnson syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo; (very rare: may affect up to 1 in 10,000 people).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow skin, dark urine and tiredness which can be symptoms of liver problems (very rare: may affect up to 1 in 10,000 people).</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine may in very rare cases affect the white blood cells leading to immune deficiency. If you have an infection with symptoms such as fever with a <strong>severely </strong>reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for you to give information about your medication at this time (very rare: may affect up to 1 in 10,000 people).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe liver problems leading to liver failure and a disease of the brain, which may cause you to become confused or behave strangely, and/or feel drowsy (encephalopathy) (very rare: may affect up to 1 in 10,000 people).</p><p>&nbsp;</p><p>Other side effects include:</p><p>&nbsp;</p><p><strong>Common</strong>, may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea) or being sick (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Benign polyps in the stomach</p><p>&nbsp;</p><p><strong>Uncommon</strong>, may affect up to 1 in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen hands, ankles or feet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleeplessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; needles and pins sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood tests that check how the liver is working</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lumpy rash (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fracture of the hip, wrist or spine (if this medicine is used in high doses and over long duration)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spinning feeling (vertigo)</p><p>&nbsp;</p><p><strong>Rare</strong>, may affect up to 1 in 1,000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood problems such as a reduced number of white cells or platelets (this can cause weakness, bruising or make infections more likely)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of sodium in the blood (this may cause weakness, being sick (vomiting) and cramps) feeling agitated, confused or depressed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taste changes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suddenly feeling wheezy or short of breath (constriction of the airways)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the mouth lining</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash on exposure to sunshine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint or muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Very rare</strong>, may affect up to 1 in 10,000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; equal lack of white and red blood cells and blood platelets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seeing, feeling or hearing things that are not there (hallucinations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast enlargement in men</p><p>&nbsp;</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking this medicine for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If you get any of these symptoms, tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation in the gut (microscopic colitis) leading to diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, possibly with pain in the joints.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the blister or bottle after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><em>For HDPE bottles:</em></p><p>Storage conditions before opening of the HDPE bottle: Do not store above 25&deg;C.</p><p>&nbsp;</p><p>Storage conditions after first opening of the HDPE bottle: Do not store above 25&deg;C.</p><p>Shelf life after first opening of the bottle: 6 months.</p><p>Keep the container tightly closed in order to protect from moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is esomeprazole. Each gastro-resistant tablet contains 20 mg esomeprazole (as magnesium dihydrate).</p><p>-The other ingredients are:</p><p><em>Tablet core: </em>sucrose, maize starch, liquid glucose, hydroxypropylcellulose, povidone, talc, titanium dioxide (E171), methacrylic acid-ethyl acrylate copolymer (1:1), glycerol monostearate, propylene glycol, stearic acid, polysorbate 80, simeticone, microcrystalline cellulose, macrogol 6000, crospovidone, silica colloidal anhydrous, magnesium stearate.</p><p><em>Tablet coating: </em>hypromellose, macrogol 6000, titanium dioxide (E171), talc, red and yellow iron oxide (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Esomep 20 mg are light pink oval film-coated tablets. 

Esomep are available in HDPE bottles with 7, 14, 15, 28, 30, 56, 60, 90, 98, 100 and 250 gastro-resistant tablets.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Marketing Authorisation Holder</p><p>Sandoz Farmaceutica S.A.,</p><p>Centro Empresarial Osa Mayor,</p><p>Madrid, Spain</p><p>&nbsp;</p><p>Manufacturer</p><p>Salutas Pharma GmbH</p><p>Otto-von-Guericke-Allee 1, 39179</p><p>Barleben,</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار إيزوميب 20 مجم على دواء يُسمى إيزوميبرازول. ينتمي هذا الدَّواء إلى مجموعة من الأدوية تُسمى &lsquo;مثبطات مضخة البروتون&rsquo;. وهي تعمل عن طريق تقليل كمية الحمض التي تنتجها معدتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار إيزوميب 20 مجم لعلاج الحالات الآتية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغون</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;مرض الجَزْر (الارتجاع) المَعِدِيّ المَريئِيّ&rsquo; فهنا يهرب حَمض المعدة إلى المريء (الأنبوب الذي يربط الحلق بالمعدة لديك) مما يُسبب ألمًا والتهابات وحموضة (حرقة الفؤاد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح في المعدة أو الجزء العلوي من الأمعاء المصابة بالبكتيريا التي تُسمى <em>&quot;</em><em>الملوية البوابية</em><em>&quot;</em>. إذا كنت مُصابًا بهذه الحالة، فقد يصف طبيبك أيضًا المضادات الحيوية لعلاج العدوى والسَّماح للقرحة بالشفاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح المعدة النَّاجمة عن الأدوية التي تسمى مضادات الالتهاب غير الستيرويدية. من الممكن أن يُستخدم عقار إيزوميب 20 مجمأيضًا لوقف تكون قرح المعدة إذا كنت تتناول مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كمية كبيرة من الحمض في المعدة النَّاجم عن نمو في البنكرياس (متلازمة زولينجر إليسون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج لفترة طويلة بعد الوقاية من عودة النزيف النَّاجم عن القرح بعقار إيزوميب عن طريق الوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المراهقون الذين تبلغ أعمارهم&nbsp; </u><u>12 </u><u>عامًا فأكبر</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;مرض الجَزْر (الارتجاع) المَعِدِيّ المَريئِيّ&rsquo; فهنا يهرب حَمض المعدة إلى المريء (الأنبوب الذي يربط الحلق بالمعدة لديك) مما يسبب ألمًا والتهابات وحموضة (حرقة الفؤاد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح في المعدة أو الجزء العلوي من الأمعاء المصابة بالبكتيريا التي تُسمى: &quot;الملوية البوابية&quot;. إذا كنت مُصابًا بهذه الحالة، فقد يصف طبيبك أيضًا المضادات الحيوية لعلاج العدوى والسَّماح للقرحة بالشفاء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول عقار إيزوميب</strong> 20 مجم<strong>في الحالات الآتية</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>تعاني من حساسية</strong> تجاه إيزوميبرازول أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>تعاني من حساسية</strong> تجاه أدوية مماثلة تحتوي على مادة فعالة لها أسماء تنتهي بـ &ndash;برازول (مثل: بانتوبرازول، لانسوبرازول، رابيبرازول، أوميبرازول)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الأدوية التي تحتوي على المادة الفعالة <strong>نلفينافير</strong>، وهو دواء لعلاج عدوى فيروس نقص المناعة البشري.</p><p dir="RTL">لا تتناول عقار إيزوميب 20 مجمإذا كان ينطبق عليك أي من الحالات أعلاه. إذا لم تكن متأكدًا، تحدَّث مع طبيبك أو الصيدلي الخاص بك قبل تناول عقار إيزوميب 20 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك قبل تناول عقار إيزوميب 20 مجم في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل شديدة بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل شديدة بالكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بصدد الخضوع لإجراء اختبار معين بالدَّم (كروموجرانين &quot;أ&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصبت من قبل بتفاعل جلدي بعد العلاج بدواء مماثل لعقار إيزوميب الذي يقلل من حمض المعدة.</p><p dir="RTL">إذا أُصبت بطفح جلدي، خاصَّة في المناطق المعرضة للشمس، فأخبر طبيبك في أقرب وقت ممكن؛ حيث قد تحتاج إلى إيقاف علاجك بعقار إيزوميب. تذكر أيضًا ذكر أي آثار مرض أخرى مثل ألم بالمفاصل لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يخفي عقار إيزوميب 20 مجم أعراض الأمراض الأخرى. <strong>لذلك، إذا حدث لك أي مما يلي قبل أن تبدأ بتناول عقار إيزوميب </strong>20 مجم<strong> </strong><strong>&nbsp;أو أثناء تناوله، فتحدَّث إلى طبيبك على الفور</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فقدت الكثير من وزنك دون سبب ولديك مشاكل في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت لألم بالمعدة أو عسر الهضم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بدأت في تقيؤ الطعام أو الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخرجت بُرازًا أسود (برازًا به بقع من الدَّم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا وُصف لك عقار إيزوميب 20 مجم &nbsp;&quot;عند اللزوم&quot;، يجب عليك الاتصال بطبيبك إذا استمرت الأعراض أو تغيرت في شكلها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن تناول مثبط مضخة البروتون مثل عقار إيزوميب 20 مجم، خاصَّة على مدار أكثر من عام واحد، قد يزيد من خطر الإصابة بكسور في الورك أو الرسغ أو العمود الفقري بشكل طفيف. أخبر طبيبك إذا كنت مُصابًا بمرض هشاشة العظام أو إذا كنت تتناول الكورتيكوستيرويدات (التي يمكن أن تزيد من خطر الإصابة بهشاشة العظام).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يُوصى باستخدام عقار إيزوميب 20 مجمللأطفال أقل من عمر 12 عامًا، حيث لا توجد بيانات كافية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وعقار إيزوميب</strong> 20 مجم</p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى. يرجع ذلك إلى أنَّ عقار إيزوميب 20 مجم من الممكن أن يُؤثر على طريقة عمل بعض الأدوية وقد يكون لبعض الأدوية تأثير على عقار إيزوميب 20 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول عقار إيزوميب 20 مجم إذا كنت تتناول دواءً يحتوي على نيلفينافير (يُستخدم لعلاج فيروس نقص المناعة البشري).</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن أن تُؤثر الأدوية التَّالية على عقار إيزوميب 20 مجمأو تتأثر به:</p><p dir="RTL">&middot;&nbsp;&nbsp; <strong>أتازانافير، </strong>دواء لعلاج عدوى فيروس نقص المناعة البشري.</p><p dir="RTL">&middot;&nbsp;&nbsp; <strong>كيتوكونازول، أتراكونازول، </strong>أو<strong> فوريكونازول،</strong> أدوية تُستخدم لعلاج العدوى الفطرية.</p><ul><li dir="RTL">إذا لزم الأمر، سيقوم طبيبك بتعديل جرعة إيزوميب 20 مجم للمرضى الذين يتم علاجهم بشكل مستمر، والمرضى الذين يعانون من انخفاض شديد في وظائف الكبد.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp; <strong>إرلوتينيب </strong>(يُستخدم لعلاج السرطان).</p><p dir="RTL">&middot;&nbsp;&nbsp; الأدوية التي يتم استقلابها بواسطة إنزيم معين مثل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ديازيبام، </strong>دواء مهدئ؛ للتهدئة وتحفيز النوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سيتالوبرام، إيميبرامين، كلوميبرامين، </strong>أدوية لعلاج الاكتئاب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فينيتوين، </strong>دواء لعلاج الصرع وبعض حالات الألم.</p><p dir="RTL">إذا لزم الأمر، يجب على طبيبك خفض جرعة هذه الأدوية، وخاصةً أثناء الاستخدام العارض. إذا كنت تتناول فينيتوين، فسيقوم طبيبك بمراقبة مستويات الفينيتوين لديك في الدَّم، خاصةً عند بدء العلاج بعقار إيزوميب 20 مجمأو الانتهاء منه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>وارفارين، فينوبروكومون، أسينوكومارول، </strong>أدوية تُستخدم لمنع التجلط الطبيعي للدَّم. سيقوم طبيبك بمراقبة قيم تجلط الدَّم، خاصةً عند بدء العلاج بعقار إيزوميب 20 مجمأو الانتهاء منه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سيلوستازول </strong>(يُستخدم لعلاج العرج المتقطع - ألم في ساقيك عند المشي والذي يكون بسبب إمداد الدَّم غير الكافي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سيسابريد، </strong>دواء لعلاج مشاكل المعدة والأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ميثوتركسات </strong>(دواء للعلاج الكيميائي يُستخدم بجرعات مرتفعة لعلاج السرطان) - إذا كنت تتناول جرعة مرتفعة من ميثوتريكسات، فقد يوقف طبيبك العلاج بعقار إيزوميب 20 مجم بشكل مؤقت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريفامبيسين، </strong>مضاد حيوي (يُستخدم لعلاج مرض السل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نبتة سانت جونز،</strong> علاج عُشبي لعلاج الاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ديجوكسين، </strong>دواء لعلاج حالات القلب المختلفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كلوبيدوجريل، </strong>يُستخدم للوقاية من أحداث تصلب الشرايين (على سبيل المثال النوبة القلبية أو السكتة الدماغية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تاكروليموس،</strong> يُستخدم للوقاية من الرفض الذي يحدث بعد عملية زرع الأعضاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا وصف طبيبك المضادات الحيوية <strong>أموكسيسيلين</strong> <strong>وكلاريثروميسين</strong> وكذلك عقار إيزوميب 20 مجم لعلاج القرح النَّاجمة عن عدوى <em>الملوية البوابية</em>، فمن المهم جدًّا أن تخبر طبيبك عن أي أدوية أخرى تتناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناوُل هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحمل</strong></p><p dir="RTL">سيقرر طبيبكِ ما إذا كان يمكنكِ تناول عقار إيزوميب 20 مجم أثناء هذا الوقت أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الرَّضاعة الطبيعية</strong></p><p dir="RTL">من غير المعروف ما إذا كان عقار إيزوميب 20 مجم يمر إلى لبن الأم أم لا. لذلك، يجب عليكِ عدم تناوُل عقار إيزوميب 20 مجمإذا كنتِ مرضعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس من المُرجح أن عقار إيزوميب<strong> </strong>20 مجميُؤثر في قدرتك على القيادة أو استخدام أية أدوات أو آلات. مع ذلك، قد تحدث آثار جانبية مثل الدوخة وعدم وضوح الرؤية بشكل غير شائع أو بشكل نادر (انظر القسم 4). إذا أُصبت بذلك، فيجب عليك عدم القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار إيزوميب</strong> 20 مجم<strong>على جلوكوز وسكروز</strong></p><p>إذا كان طبيبك قد أخبرك بأنك <strong>لا تتحمل بعض أنواع السكريات،</strong> فاتصل به قبل تناول هذا المنتج الدَّوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&middot;&nbsp;&nbsp; لا يُوصى باستخدام عقار إيزوميب 20 مجمفي الأطفال الذين تقل أعمارهم عن 12 عامًا.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تتناول هذا الدَّواء لفترة طويلة، فسيرغب طبيبك في مراقبتك (خاصةً إذا كنت تتناوله لمدة تزيد عن عام واحد).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا أخبرك طبيبك بتناوُل هذا الدَّواء عند اللزوم، فأخبر طبيبك إذا تغيرت علامات المرض لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>ما هي الكمية التي يجب أن تتناولها؟</strong></li></ul><p dir="RTL">&middot;&nbsp;&nbsp; سيخبرك طبيبك بعدد الأقراص التي ستتناولها ولأي مدة تتناولها. سيعتمد ذلك على حالتك وعمرك وحالة الكبد لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp; الجرعات المعتادة موضحة أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغون</u></p><p dir="RTL"><strong>لعلاج الحموضة </strong><strong>(</strong><strong>حُرقة الفؤاد</strong><strong>) </strong><strong>الناجمة عن مرض الجَزْر</strong><strong>(</strong><strong>الارتجاع</strong><strong>) </strong><strong>المَعِدِيّ المَريئِيّ</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وجد طبيبك أن أنبوب الطعام لديك (المريء) قد تعرض لأضرار طفيفة، فإنَّ الجرعة المعتادة هي قرصان مرة واحدة يوميًّا لمدة 4 أسابيع. قد يخبرك طبيبك بتناوُل الجرعة نفسها لمدة 4 أسابيع أخرى إذا لم يلتئم المريء بعد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة بمجرد التئام المريء قرصًا واحدًا مقاومًا للمعدة من عقار إيزوميب 20 مجم مرة واحدة في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يحدث تلف بالمريء لديك، تكون الجرعة المعتادة قرصًا واحدًا مقاومًا للمعدة من عقار إيزوميب20 مجم مرة واحدة في اليوم. بمجرد السيطرة على الحالة، قد يخبرك طبيبك بتناول الدَّواء الخاص بك عند اللزوم، حتى الوصول إلى الجرعة القصوى البالغة قرصًا واحدًا مقاومًا للمعدة من عقار إيزوميب 20 مجم كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل شديدة بالكبد، فقد يعطيك طبيبك جرعة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج القرح النَّاجمة عن عدوى<em> الملوية البوابية</em> ولإيقافها من المعاودة</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة قرصًا واحدًا مقاومًا للمعدة من عقار إيزوميب 20 مجم مرتين في اليوم لمدة أسبوع واحد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك طبيبك أيضًا بتناوُل المضادات الحيوية على سبيل المثال، أموكسيسيلين وكلاريثروميسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج قرح المعدة الناجمة عن مضادات الالتهاب غير الستيرويدية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة قرصًا واحدًا مقاومًا للمعدة من عقار إيزوميب 20 مجم مرة واحدة في اليوم لمدة 4 إلى 8 أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للوقاية من قرح المعدة إذا كنت تتناول مضادات الالتهاب غير الستيرويدية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة قرصًا واحدًا مقاومًا للمعدة من عقارإيزوميب 20 مجم مرة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج وجود كمية كبيرة من الحمض في المعدة النَّاجم عن نمو في البنكرياس </strong><strong>(</strong><strong>متلازمة زولينجر إليسون</strong><strong>):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة قرصين مرتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بتعديل الجرعة حسب احتياجاتك وسيقرر أيضًا المدة التي تحتاج لتناول الدَّواء خلالها. تبلغ الجرعة القصوى 80 مجم مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلاج لفترة طويلة بعد الوقاية من عودة النزيف النَّاجم عن القرح باستخدام عقار إيزوميب عن طريق الوريد</strong><strong>:</strong></p><p dir="RTL">تبلغ الجرعة المعتادة قرصين مرة واحدة في اليوم لمدة 4 أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المراهقون </u><u>(12 </u><u>عامًا أو أكبر</u><u>)</u></p><p dir="RTL"><strong>لعلاج الحموضة </strong><strong>(</strong><strong>حُرقة الفؤاد</strong><strong>) </strong><strong>النَّاجمة عن مرض الجَزْر</strong><strong>(</strong><strong>الارتجاع</strong><strong>) </strong><strong>المَعِدِيّ المَريئِيّ</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وجد طبيبك أن أنبوب الطعام لديك (المريء) قد تعرض لأضرار طفيفة، فإنَّ الجرعة المعتادة هي قرصان مرة واحدة يوميًّا لمدة 4 أسابيع. قد يخبرك طبيبك بتناوُل الجرعة نفسها لمدة 4 أسابيع أخرى إذا لم يلتئم المريء بعد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة بمجرد التئام المريء قرصًا واحدًا مقاومًا للمعدة من عقار إيزوميب 20 مجم مرة واحدة في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يحدث تلف بالمريء لديك، تكون الجرعة المعتادة قرصًا واحدًا مقاومًا للمعدة من عقار إيزوميب20 مجم مرة واحدة في اليوم. بمجرد السيطرة على الحالة، قد يخبرك طبيبك بتناول الدَّواء الخاص بك عند اللزوم، حتى الوصول إلى الجرعة القصوى البالغة قرصًا واحدًا مقاومًا للمعدة من عقار إيزوميب 20 مجم كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل شديدة بالكبد، فقد يعطيك طبيبك جرعة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج القرح النَّاجمة عن عدوى<em> الملوية البوابية</em> ولإيقافها من المعاودة</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة قرصًا واحدًا مقاومًا للمعدة من عقار إيزوميب 20 مجم مرتين في اليوم لمدة أسبوع واحد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك طبيبك أيضًا بتناوُل المضادات الحيوية على سبيل المثال، أموكسيسيلين وكلاريثروميسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل هذا الدَّواء</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول أقراصك في أي وقت من اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول أقراصك مع الطعام أو على معدة فارغة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع أقراصك كاملة مع بعض من الماء. لا تمضغ الأقراص أو تطحنها. يرجع ذلك إلى أنَّ الأقراص تحتوي على كريات مغلفة تمنع الدَّواء من التحلل بواسطة الحمض في معدتك. من المهم عدم إتلاف الكريات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماذا تفعل إذا كانت لديك مشكلة في بلع الأقراص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشكلة في بلع الأقراص:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعها في كوب من المياه غير الغازية (لا توجد به فقاعات). لا تستخدم أي سوائل أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلّب حتى تتفتت الأقراص (لن يكون الخليط صافيًا). ثم اشرب الخليط فورًا أو في غضون 15 دقيقة. قلّب الخليط دائمًا قبل شربه مباشرةً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للتَّأكد من أنك قد شربت الدَّواء بالكامل، اشطف الكوب جيدًا بنصف كوب من الماء واشربه. تحتوي القطع الصلبة على دواء - لا تمضغها أو تطحنها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تتمكن من البلع على الإطلاق، يمكن خلط القرص ببعض الماء ووضعه في سرنجة. يمكن عندئذ إعطاؤها لك عن طريق أنبوب مباشرة إلى معدتك (&quot;أنبوب المعدة&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من عقار إيزوميب</strong> 20 مجم</p><p dir="RTL">إذا تناولت كمية أكثر مما وصفها طبيبك من عقار إيزوميب 20 مجم، تحدَّث إلى طبيبك أو الصيدلي الخاص بك فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناوُل عقار إيزوميب </strong>20 مجم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أغفلت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها. مع ذلك، إذا كان قد اقترب موعد الجرعة التَّالية، فتجاوز الجرعة التي أغفلتها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول عقار إيزوميب </strong>20 مجم</p><p dir="RTL">تناول دائمًا الجرعة الموصوفة طوال المدة التي يصفها لك طبيبك. إيقاف العلاج بشكل مؤقت أو إيقاف العلاج بشكل دائم دون مشورة الطبيب قد يقلل من نجاح علاجك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاسأل طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا لاحظت أيًّا من الآثار الجانبية الخطيرة التَّالية، فتوقف عن تناول هذا الدَّواء واتصل بطبيب على الفور</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز مفاجئ بالصدر، تورم بالشفتين واللسان والحلق أو الجسم، طفح جلدي، إغماء أو صعوبات في البلع (تفاعلات حساسية شديدة) (نادرة: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد مع بثور أو تقشير. قد يكون هناك أيضًا بثور شديدة، نزيف في الشفتين والعينين والفم والأنف والأعضاء التَّناسلية أو الحمّى المرتفعة وألم بالمفاصل. قد يكون ذلك &quot;احمرار متعدد الأشكال&quot;، &quot;متلازمة ستيفنز جونسون&quot; أو &quot;انحلال البشرة النخري التَّسَمُّمِيّ&quot; (نادرة جدًّا: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10,000 شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار بالجلد، بول داكن وتعب، وهي قد تكون أعراضًا على مشاكل بالكبد (نادرة جدًّا: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10,000 شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُؤثر هذا الدَّواء في حالات نادرة جدًّا على خلايا الدَّم البيضاء مما يُؤدي إلى نقص المناعة. إذا كنت مصابًا بعدوى ذات أعراض مثل الحُمّى مع انخفاض <strong>شديد</strong> في الحالة العامة أو الحُمّى ذات أعراض عدوى موضعية مثل ألم بالرَّقبة أو الحلق أو الفم أو صعوبات في التبول، فيجب عليك استشارة طبيبك في أقرب وقت ممكن حتى تتمكن من استبعاد نقص خلايا الدَّم البيضاء (ندرة خلايا المحببات) عن طريق اختبار بالدَّم. من المهم بالنسبة لك تقديم معلومات عن دوائك في هذا الوقت (نادرة جدًّا: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10,000 شخص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل شديدة في الكبد تُؤدي إلى فشل الكبد ومرض في المخ، مما قد يسبب لك الارتباك أو التَّصرف بشكل غريب، و/ أو الشعور بالنعاس (اعتلال دماغي) (نادرة جدًّا: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10,000 شخص).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية الأخرى:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة، </strong>قد تُؤثر على ما يصل إلى شخص واحد من كل ١٠&nbsp;أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التأثيرات على المعدة أو الأمعاء: إسهال، ألم بالمعدة، إمساك، ريح (انتفاخ البطن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (الغثيان)، أو إعياء (القيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلائل حميدة بالمعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة،</strong> قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين، أو الكاحلين، أو القدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (أرق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بوخز مثل &quot;الإبر والمسامير&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جُفاف الفَم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في نتائج اختبارات الدَّم التي تفحص كفاءة عمل الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي كتلي (شرى (أرتكاريا)).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسر بالورك أو الرسغ أو العمود الفقري (إذا تم استخدام هذا الدَّواء بجرعات مرتفعة وعلى مدار فترة طويلة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران (دوار).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة،</strong> قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الدَّم مثل انخفاض تعداد خلايا الدَّم البيضاء أو الصفائح الدَّموية (قد يُؤدي ذلك إلى الضعف أو الإصابة بكدمات أو تجعلك أكثر عُرضة للإصابة بالعدوى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدَّم (قد يُسبب ذلك ضعفًا، أو إعياء (قيئًا) وتقلصات) والشعور بتهيج أو الالتباس أو الاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات بحاسة التَّذوق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور مفاجئ بأزيز أو ضيق النَّفس (تَضَيّق الشعب الهوائية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى تُسمى &quot;السُّلَاق&quot; والتي من الممكن أن تُؤثر على الأمعاء وتكون ناجمة عن الفطريات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي عند التَّعرض لضوء الشمس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل أو العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور عام بالإعياء (توعُّك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التَّعرق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا،</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10,000&nbsp;شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص متساوٍ في خلايا الدَّم البيضاء والحمراء والصفائح الدَّموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوانية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو إحساس أو سماع أشياء غير موجودة (هلَاوِس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكُلى شديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي لدى الرجال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong>(لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول هذا الدَّواء لأكثر من ثلاثة أشهر، فمن المحتمل أن تنخفض مستويات الماغنسيوم لديك في الدَّم. من الممكن ملاحظة انخفاض مستويات الماغنسيوم على أنها إرهاق وانقباضات عضلية غير إرادية وتوهان وتشنجات ودوخة وزيادة معدل ضربات القلب. اذا أصبت بأيٍّ من هذه الأعراض، فأخبر طبيبك فورًا. من الممكن أن يُؤدي انخفاض مستويات الماغنسيوم أيضًا إلى انخفاض مستويات البوتاسيوم أو الكالسيوم في الدَّم. قد يقرر طبيبك إجراء اختبارات دم منتظمة؛ لمراقبة مستويات الماغنسيوم لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الأمعاء (التهاب القولون المجهري) الذي يُؤدي إلى الإسهال.</p><p>طفح جلدي، من المحتمل أن يكون مصحوبًا بألم في المفاصل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والشريط والزجاجة بعد كلمة &quot;EXP&quot;&nbsp; يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>بالنسبة لزجاجات البولي إيثيلين عالي الكثافة</em><em>:</em></p><p dir="RTL">ظروف التَّخزين قبل فتح زجاجة البولي إيثيلين عالي الكثافة: لا تقم بالتَّخزين في درجة حرارة تتعدى 25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ظروف التَّخزين بعد فتح زجاجة البولي إيثيلين عالي الكثافة لأول مرة: لا تقم بالتَّخزين في درجة حرارة تتعدى 25 درجة مئوية.</p><p dir="RTL">عمر التَّخزين بعد فتح الزجاجة لأول مرة: 6 أشهر.</p><p dir="RTL">احتفظ بالعبوة محكمة الإغلاق لحمايتها من الرطوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إيزوميبرازول. يحتوي كل قرص مقاوم للمعدة على 20 مجم من إيزوميبرازول (في هيئة ثنائي هيدرات الماغنسيوم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -المكونات الأخرى هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>محتوى القرص الدَّاخلي</em><em>: </em>سكروز،&nbsp; نشا الذرة، جلوكوز سائل، هيدروكسي بروبيل سليلوز، بوفيدون، تلك، ثاني أكسيد التيتانيوم (E171)، حمض الميثاكريليك - بوليمر إيثيل أكريليت المشترك (1: 1)، أحادي ستيارات الجليسيرول، جليكول البروبيلين، حَمْضُ الستياريك، بوليسوربات 80، سيمتيكون، سيليلوز دقيق التبلور، ماكروجول 6000، كروسبوفيدون، سيليكا غروية غير مائية، سترات الماغنسيوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الغلاف الخارجي للقرص</em><em>: </em>هيبروميلوز، ماكروجول 6000، ثاني أكسيد التيتانيوم (E171)، تلك، أكسيد الحديد الأحمر والأصفر ((E172.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقارإيزوميب 20 مجم عبارة عن أقراص مغلفة بيضاوية الشَّكل ذات لون وردي فاتح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوافر عقارإيزوميبفي زجاجات من البولي إيثيلين عالي الكثافة تحتوي على 7، 14، 15، 28، 30، 56، 60، 90، 98، 100 و250 قرصًا مقاومًا للمعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق</strong></p><p dir="RTL">ساندوز للمنتجات الدَّوائية، شركة مساهمة،</p><p dir="RTL">مركز أوسا مايور للأعمال،</p><p dir="RTL">مدريد، إسبانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL">جهة التَّصنيع</p><p dir="RTL">سالوتاس فارما المحدودة</p><p dir="RTL">أوتو فون-جوريك آللي 1، 39179</p><p dir="RTL">بارليبين،</p><p>ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
                                                                                                                                                                          05/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esomep 20 mg gastro-resistant tablets 
Esomep 40 mg gastro-resistant tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each gastro-resistant tablet contains 20 mg esomeprazole (as magnesium dihydrate). Each gastro-resistant tablet contains 40 mg esomeprazole (as magnesium dihydrate).

Excipient(s) with known effect:
Each 20 mg gastro-resistant tablet contains 12.90 mg – 14.76 mg sucrose and 0.81 mg glucose. Each 40 mg gastro-resistant tablet contains 25.81 mg – 29.52 mg sucrose and 1.61 mg glucose.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gastro-resistant tablet
20 mg:
Light pink oval film-coated tablet.
40 mg:
Pink oval film-coated tablet with a score-line on both sides. The tablet can be divided into equal doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esomep 20 mg/40 mg gastro-resistant tablets are indicated for:</p><p><u>Adults</u></p><p><strong>Gastro-Oesophageal Reflux Disease (GORD)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of erosive reflux oesophagitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long-term management of patients with healed oesophagitis to prevent relapse</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptomatic treatment of gastro-oesophageal reflux disease (GORD)</p><p>&nbsp;</p><p><strong>In combination with appropriate antibacterial therapeutic regimens for the eradication of</strong></p><p><strong><em>Helicobacter pylori </em></strong><strong>and</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; healing of <em>Helicobacter pylori </em>associated duodenal ulcer and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevention of relapse of peptic ulcers in patients with <em>Helicobacter pylori </em>associated ulcers.</p><p><strong>Patients requiring continued NSAID therapy</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; healing of gastric ulcers associated with NSAID therapy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk.</p><p>&nbsp;</p><p><strong>Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers Treatment of Zollinger Ellison Syndrome</strong></p><p><u>Adolescents from the age of 12 years</u></p><p>&nbsp;</p><p><strong>Gastroesophageal Reflux Disease (GORD)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of erosive reflux esophagitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long-term management of patients with healed esophagitis to prevent relapse</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptomatic treatment of gastroesophageal reflux disease (GORD)</p><p>&nbsp;</p><p>In combination with antibiotics in treatment of duodenal ulcer caused by <em>Helicobacter pylori.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><em><u>Adults</u></em></p><p><em>Gastro-Oesophageal Reflux Disease (GORD)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>treatment of erosive reflux esophagitis </u>40 mg once daily for 4 weeks.</p><p>An additional 4 weeks treatment is recommended for patients in whom oesophagitis has not healed or who have persistent symptoms.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>long-term management of patients with healed oesophagitis to prevent relapse </u>20 mg once daily.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>symptomatic treatment of gastro-oesophageal reflux disease (GORD)</u></p><p>20 mg once daily in patients without oesophagitis. If symptom control has not been achieved after 4 weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using 20 mg once daily. An on demand regimen taking 20 mg once daily, when needed, can be used. In NSAID treated patients at risk of developing gastric and duodenal ulcers, subsequent symptom control using an on demand regimen is not recommended.</p><p>&nbsp;</p><p><em>In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>healing of <em>Helicobacter pylori </em>associated duodenal ulcer and</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>prevention of relapse of peptic ulcers in patients with <em>Helicobacter pylori </em>associated ulcers </u>20 mg Esomep with 1 g amoxicillin and 500 mg clarithromycin, all twice daily for 7 days.</p><p>&nbsp;</p><p><em>Patients requiring continued NSAID therapy</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Healing of gastric ulcers associated with NSAID therapy</u>:</p><p>The usual dose is 20 mg once daily. The treatment duration is 4-8 weeks.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk</u>: 20 mg once daily.</p><p>&nbsp;</p><p><em>Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.</em></p><p>40 mg once daily for 4 weeks after i.v. induced prevention of rebleeding of peptic ulcers.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Treatment of Zollinger Ellison Syndrome</em></p><p>The recommended initial dosage is 40 mg Esomep twice daily. The dosage should then be individually adjusted and treatment continued as long as clinically indicated. Based on the clinical data available, the majority of patients can be controlled on doses between 80 mg to 160 mg esomeprazole daily. With doses above 80 mg daily, the dose should be divided and given twice daily.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Patients with impaired renal function</em></p><p>Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution (see section 5.2).</p><p>&nbsp;</p><p><em>Patients with impaired hepatic function</em></p><p>Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum dose of 20 mg esomeprazole should not be exceeded (see section 5.2).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Dose adjustment is not required in the elderly. Paediatric population</p><p><em><u>Adolescents from the age of 12 years </u></em><em>Gastroesophageal Reflux Disease (GERD)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>treatment of erosive reflux esophagitis </u>40 mg once daily for 4 weeks.</p><p>An additional 4 weeks treatment is recommended for patients in whom esophagitis has not healed or who have persistent symptoms.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>long-term management of patients with healed esophagitis to prevent relapse </u>20 mg once daily.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>symptomatic treatment of gastroesophageal reflux disease (GERD)</u></p><p>20 mg once daily in patients without esophagitis. If symptom control has not been achieved after 4 weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using 20 mg once daily.</p><p>&nbsp;</p><p><em>Treatment of duodenal ulcer caused by Helicobacter pylori</em></p><p>When selecting appropriate combination therapy, consideration should be given to official national, regional and local guidance regarding bacterial resistance, duration of treatment (most commonly</p><p>7 days but sometimes up to 14 days), and appropriate use of antibacterial agents. The treatment should be supervised by a specialist.</p><p>&nbsp;</p><p>The posology recommendation is:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Posology</p></td></tr><tr><td style="vertical-align:top"><p>30 - 40 kg</p></td><td style="vertical-align:top"><p>Combination with two antibiotics: Esomep 20 mg, amoxicillin 750 mg and clarithromycin 7.5 mg/kg body weight are all administered together twice daily for one week.</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 40 kg</p></td><td style="vertical-align:top"><p>Combination with two antibiotics: Esomep 20 mg, amoxicillin 1 g and clarithromycin 500 mg are all administered together twice daily for one week.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Children below the age of 12 years</strong></p><p>Esomep should not be used in children younger than 12 years since no data is available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>The tablets should be swallowed whole with liquid. The tablets should not be chewed or crushed.</p><p>For patients who have difficulty in swallowing, the tablets can also be dispersed in half a glass of non- carbonated water. No other liquids should be used as the enteric coating may be dissolved. Stir until the tablets disintegrate and drink the liquid with the pellets immediately or within 15 minutes. Rinse the glass with half a glass of water and drink. The pellets must not be chewed or crushed.</p><p>&nbsp;</p><p>For patients who cannot swallow, the tablets can be dispersed in non-carbonated water and administered through a gastric tube. It is important that the appropriateness of the selected syringe and tube is carefully tested. For preparation and administration instructions see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to substituted benzimidazoles or to any of the excipients listed in section 6.1.
Esomeprazole must not be used concomitantly with nelfinavir (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with esomeprazole may alleviate symptoms and delay diagnosis.</p><p>&nbsp;</p><p><u>Long term use</u></p><p>Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance.</p><p>&nbsp;</p><p><u>On demand treatment</u></p><p>Patients on on-demand treatment should be instructed to contact their physician if their symptoms change in character.</p><p>&nbsp;</p><p><u>Helicobacter pylori eradication</u></p><p>When prescribing esomeprazole for eradication of Helicobacter pylori possible active substance interactions for all components in the triple therapy should be considered. Clarithromycin is a potent inhibitor of CYP 3A4 and hence contraindications and interactions for clarithromycin should be considered when the triple therapy is used in patients concurrently taking other medicinal products metabolised via CYP 3A4 such as cisapride.</p><p>&nbsp;</p><p><u>Gastrointestinal infections</u></p><p>Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as <em>Salmonella </em>and <em>Campylobacter </em>(see section 5.1).</p><p>&nbsp;</p><p><u>Absorption of vitamin B12</u></p><p>Esomeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Hypomagnesaemia</u></p><p>Severe hypomagnesaemia has been reported in patients treated with PPIs like esomeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment</p><p>&nbsp;</p><p><u>Risk of fracture</u></p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p>&nbsp;</p><p><u>Subacute cutaneous lupus erythematosus (SCLE)</u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Esomep. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>&nbsp;</p><p><u>Combination with other medicinal products</u></p><p>Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; esomeprazole 20 mg should not be exceeded.</p><p>&nbsp;</p><p>Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with drugs metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and esomeprazole (see section 4.5). The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of esomeprazole and clopidogrel should be discouraged.</p><p>&nbsp;</p><p>When prescribing esomeprazole for on demand therapy, the implications for interactions with other pharmaceuticals, due to fluctuating plasma concentrations of esomeprazole should be considered. See section 4.5.</p><p>&nbsp;</p><p><u>Interference with laboratory tests</u></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Esomep treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p>&nbsp;</p><p><u>Excipients with known effect</u></p><p>This medicinal product contains glucose and sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of esomeprazole on the pharmacokinetics of other medicinal products</u></p><p>&nbsp;</p><p><em><u>Medicinal products with pH dependent absorption</u></em></p><p>Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption. As with other medicinal products that decrease intragastric acidity, the absorption of medicinal products such as ketoconazole, itraconazole and erlotinib can decrease and the absorption of digoxin can increase during treatment with esomeprazole. Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (up to 30% in two out of ten subjects). Digoxin toxicity has been rarely reported. However, caution should be exercised when esomeprazole is given at high doses in elderly patients. Therapeutic drug monitoring of digoxin should then be reinforced.</p><p>&nbsp;</p><p><em><u>Protease inhibitors</u></em></p><p>Omeprazole has been reported to interact with some protease inhibitors. The clinical importance and the mechanisms behind these reported interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the protease inhibitors. Other possible interaction mechanisms are via inhibition of CYP2C19. For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended. Co-administration of omeprazole (40 mg once daily) with atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 75% decrease in AUC, Cmax and Cmin). Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg once daily) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared with the exposure observed with atazanavir 300 mg/ritonavir 100 mg once daily without omeprazole 20 mg once daily. Co- administration of omeprazole (40 mg once daily) reduced mean nelfinavir AUC, Cmax and Cmin by 36&ndash; 39 % and mean AUC, Cmax and Cmin for the pharmacologically active metabolite M8 was reduced by 75-92%.</p><p>Due to the similar pharmacodynamic effects and pharmacokinetic properties of omeprazole and esomeprazole, concomitant administration with esomeprazole and atazanavir is not recommended (see section 4.4) and concomitant administration with esomeprazole and nelfinavir is contraindicated (see section 4.3.).</p><p>For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported during concomitant omeprazole treatment (40 mg once daily). Treatment with omeprazole 20 mg once daily had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir). Treatment with esomeprazole 20 mg once daily had no effect on the exposure of amprenavir (with and without concomitant ritonavir). Treatment with omeprazole 40 mg once daily had no effect on the exposure of lopinavir (with concomitant ritonavir).</p><p>&nbsp;</p><p><em><u>Medicinal products metabolised by CYP2C19</u></em></p><p>Esomeprazole inhibits CYP2C19, the major esomeprazole metabolising enzyme. Thus, when esomeprazole is combined with medicinal products metabolised by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin, etc., the plasma concentrations of these medicinal products may be increased and a dose reduction could be needed. This should be considered especially when prescribing esomeprazole for on demand therapy.</p><p>&nbsp;</p><p><em><u>Diazepam</u></em></p><p>Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Phenytoin</u></em></p><p>Concomitant administration of 40 mg esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn.</p><p>&nbsp;</p><p><em><u>Voriconazole</u></em></p><p>Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate) Cmax and AUC&tau; by 15% and 41%, respectively.</p><p>&nbsp;</p><p><em><u>Warfarin</u></em></p><p>Concomitant administration of 40 mg esomeprazole to warfarin-treated patients in a clinical trial showed that coagulation times were within the accepted range. However, post-marketing, a few isolated cases of elevated INR of clinical significance have been reported during concomitant treatment. Monitoring is recommended when initiating and ending concomitant esomeprazole treatment during treatment with warfarin or other coumarine derivatives.</p><p>&nbsp;</p><p><em><u>Cilostazol</u></em></p><p>Omeprazole as well as esomeprazole act as inhibitors of CYP2C19. Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.</p><p>&nbsp;</p><p><em><u>Cisapride</u></em></p><p>In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half- life (t1/2) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged when cisapride was given in combination with esomeprazole (see also section 4.4).</p><p>&nbsp;</p><p><em><u>Clopidogrel</u></em></p><p>Results from studies in healthy subjects have shown a pharmacokinetic (PK)/ pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg p.o.daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40% and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%.</p><p>&nbsp;</p><p>When clopidogrel was given together with a fixed dose combination of esomeprazole 20 mg + ASA 81 mg compared to clopidogrel alone in a study in healthy subjects there was a decreased exposure by almost 40% of the active metabolite of clopidogrel. However, the maximum levels of inhibition of (ADP induced) platelet aggregation in these subjects were the same in the clopidogrel and the clopidogrel + the combined (esomeprazole + ASA) product groups.</p><p>&nbsp;</p><p>Inconsistent data on the clinical implications of a PK/PD interaction of esomeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution concomitant use of clopidogrel should be discouraged.</p><p>&nbsp;</p><p><em><u>Tacrolimus</u></em></p><p>Concomitant administration of esomeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dose of tacrolimus adjusted if needed.</p><p>&nbsp;</p><p><em><u>Methotrexate</u></em></p><p>&nbsp;</p><p><em>&nbsp;</em></p><p>When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of esomeprazole may need to be considered.</p><p>&nbsp;</p><p><em><u>Investigated medicinal products with no clinically relevant interaction </u></em><em>Amoxicillin and quinidine</em></p><p>Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin or quinidine.</p><p>&nbsp;</p><p><em>Naproxen or rofecoxib</em></p><p>Studies evaluating concomitant administration of esomeprazole and either naproxen or rofecoxib did not identify any clinically relevant pharmacokinetic interactions during short-term studies.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on the pharmacokinetics of esomeprazole</u></p><p>&nbsp;</p><p><em><u>Medicinal products which inhibit CYP2C19 and/or CYP3A4</u></em></p><p>Esomeprazole is metabolized by CYP2C19 and CYP3A4. Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg twice daily), resulted in a doubling of the exposure (AUC) to esomeprazole. Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4 may result in more than doubling of the esomeprazole exposure. The CYP2C19 and CYP 3A4 inhibitor voriconazole increased omeprazole AUC&tau; by 280%. A dose adjustment of esomeprazole is not regularly required in either of these situations. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.</p><p>&nbsp;</p><p><em><u>Medicinal products which induce CYP2C19 and/or CYP3A4</u></em></p><p>Medicinal products known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John&rsquo;s wort) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Pregnancy</u></p><p>Clinical data on exposed pregnancies with esomeprazole are insufficient. With the racemic mixture, omeprazole, data on a larger number of exposed pregnancies from epidemiological studies indicate no malformative nor foetotoxic effect. Animal studies with esomeprazole do not indicate direct or indirect harmful effects with respect to embryonal/foetal development. Animal studies with the racemic mixture do not indicate direct or indirect harmful effects with respect to pregnancy, parturition or postnatal development. Caution should be exercised when prescribing esomeprazole to pregnant women. A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicates no malformative or foeto/neonatal toxicity of esomeprazole.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is not known whether esomeprazole is excreted in human breast milk. There is insufficient information on the effects of esomeprazole in newborns/infants. Esomeprazole should not be used during breast- feeding.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esomeprazole has minor influence on the ability to drive or use machines. Adverse reactions such as dizziness (uncommon) and blurred vision (rare) have been reported (see section 4.8). If affected, patients should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical trials (and also from post-marketing use). In addition, the safety profile is similar for different formulations, treatment indications, age groups and patient populations. No dose-related adverse reactions have been identified.</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p>The following adverse drug reactions have been identified or suspected in the clinical trials programme for esomeprazole and post-marketing. None was found to be dose-related. The reactions are classified according to the MedDRA frequency convention:</p><p>very common &ge; 1/10; common &ge; 1/100 to &lt; 1/10; uncommon &ge; 1/1,000 to &lt; 1/100; rare &ge; 1/10,000 to</p><p>&lt; 1/1,000; very rare &lt; 1/10,000; not known (frequency cannot be estimated from the available data).</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorder</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocyt openia</p></td><td style="vertical-align:top"><p>Agranulocyt osis, pancytopeni a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensiti vity reactions</p><p>e.g. fever, angioedema and anaphylactic reaction/sho ck</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Hyponatrae mia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypomagne semia (see section 4.4); severe hypomagnes aemia can correlate with hypocalcae mia.</p><p>Hypomagna semia may also be associated with hypokalaem ia.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Agitation, confusion, depression</p></td><td style="vertical-align:top"><p>Aggression, hallucinatio ns</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness, paraesthesia</p><p>,</p><p>somnolence</p></td><td style="vertical-align:top"><p>Taste disturbance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blurred vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respirator y, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospa sm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointes tinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain, constipation</p><p>, diarrhoea, flatulence, nausea/vomi ting, fundic gland polyps (benign)</p></td><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Stomatitis, gastrointesti nal candidiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Microscopic colitis</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobilia </strong><strong>ry disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased liver enzymes</p></td><td style="vertical-align:top"><p>Hepatitis with or without jaundice</p></td><td style="vertical-align:top"><p>Hepatic failure, encephalopa thy in patients with pre- existing liver disease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneo us tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dermatitis, pruritus, rash, urticaria</p></td><td style="vertical-align:top"><p>Alopecia, photosensiti vity</p></td><td style="vertical-align:top"><p>Erythema multiforme, Stevens- Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td><td style="vertical-align:top"><p>Subacute cutaneous lupus erythematos us (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoske letal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine (see section 4.4)</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia</p></td><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial nephritis; in some patients renal failure has been reported concomitant ly.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproducti ve system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecoma stia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorder and administrat ion site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Malaise, increased sweating</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>&nbsp;</p><p>&nbsp;</p><p>There is very limited experience to date with deliberate overdose. The symptoms described in connection with 280 mg were gastrointestinal symptoms and weakness. Single doses of 80 mg esomeprazole were uneventful.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD), proton pump inhibitor</p><p>ATC code: A02B C05</p><p>&nbsp;</p><p>Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Both the R- and S-isomer of omeprazole have similar pharmacodynamic activity.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+K+-ATPase</p><p>&ndash; the acid pump and inhibits both basal and stimulated acid secretion.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>After oral dosing with esomeprazole 20 mg and 40 mg the onset of effect occurs within one hour. After repeated administration with 20 mg esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6-7 hours after dosing on day five.</p><p>&nbsp;</p><p>After five days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic GORD patients. The proportion of patients maintaining an intragastric pH above 4 for at least 8, 12 and 16 hours respectively were for esomeprazole 20 mg 76%, 54% and 24%. Corresponding</p><p>proportions for esomeprazole 40 mg were 97%, 92% and 56%.</p><p>&nbsp;</p><p>Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown.</p><p>&nbsp;</p><p><u>Therapeutic effects of acid inhibition</u></p><p>Healing of reflux oesophagitis with esomeprazole 40 mg occurs in approximately 78% of patients after four weeks, and in 93% after eight weeks.</p><p>&nbsp;</p><p>One week treatment with esomeprazole 20 mg twice daily and appropriate antibiotics, results in successful eradication of <em>H. pylori </em>in approximately 90% of patients.</p><p>After eradication treatment for one week there is no need for subsequent monotherapy with antisecretory medicinal products for effective ulcer healing and symptom resolution in uncomplicated duodenal ulcers.</p><p>&nbsp;</p><p>&nbsp;</p><p>In a randomised, double blind, placebo-controlled clinical study, patients with endoscopically confirmed peptic ulcer bleeding characterised as Forrest Ia, Ib, IIa or IIb (9%, 43%, 38% and 10% respectively) were randomised to receive esomeprazole solution for infusion (n=375) or placebo (n=389). Following endoscopic hemostasis, patients received either 80 mg esomeprazole as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for 72 hours. After the initial 72 hour period, all patients received open-label 40 mg oral esomeprazole for 27 days for acid suppression. The occurrence of rebleeding within 3 days was 5.9% in the esomeprazole treated group compared to 10.3% for the placebo group. At 30 days post-treatment, the occurrence of rebleeding in the esomeprazole treated versus the placebo treated group was 7.7% vs 13.6%.</p><p>&nbsp;</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p>&nbsp;</p><p>An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in both children and adults during long term treatment with esomeprazole. The findings are considered to be of no clinical significance.</p><p>&nbsp;</p><p>During long-term treatment with antisecretory medicinal products gastric glandular cysts have been reported to occur at a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.</p><p>&nbsp;</p><p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as <em>Salmonella</em>, Campylobacter and, in hospitalised patients, possibly also <em>Clostridium difficile</em>.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>In two studies with ranitidine as an active comparator, esomeprazole showed better effect in healing of gastric ulcers in patients using NSAIDs, including COX-2 selective NSAIDs.</p><p>&nbsp;</p><p>In two studies with placebo as comparator, esomeprazole showed better effect in the prevention of gastric and duodenal ulcers in patients using NSAIDs (aged &gt; 60 and/or with previous ulcer), including COX-2 selective NSAIDs.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>In a study in paediatric GORD patients (&lt;1 to 17 years of age) receiving long-term PPI treatment, 61% of the children developed minor degrees of ECL cell hyperplasia with no known clinical significance and with no development of atrophic gastritis or carcinoid tumours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Esomeprazole is acid labile and is administered orally as enteric-coated granules. In vivo conversion to the R-isomer is negligible. Absorption of esomeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. The absolute bioavailability is 64% after a single dose of 40 mg and increases to 89% after repeated once-daily administration. For 20 mg esomeprazole the corresponding values are 50% and 68%, respectively.</p><p>&nbsp;</p><p>&nbsp;</p><p>Food intake both delays and decreases the absorption of esomeprazole although this has no significant influence on the effect of esomeprazole on intragastric acidity.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent volume of distribution at steady state in healthy subjects is approximately 0.22 l/kg body weight. Esomeprazole is 97% plasma protein bound.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Esomeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy-and desmethyl metabolites of esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolisers.</p><p>&nbsp;</p><p>Total plasma clearance is about 17 l/h after a single dose and about 9 l/h after repeated administration. The plasma elimination half-life is about 1.3 hours after repeated once-daily dosing. Esomeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once- daily administration.</p><p>&nbsp;</p><p>The major metabolites of esomeprazole have no effect on gastric acid secretion. Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the faeces. Less than 1% of the parent drug is found in urine.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg twice daily. The area under the plasma concentration-time curve increases with repeated administration of esomeprazole. This increase is dose-dependent and results in a more than dose proportional increase in AUC after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by esomeprazole and/or its sulphone metabolite.</p><p>&nbsp;</p><p><u>Special patient populations</u></p><p>&nbsp;</p><p><em><u>Poor metabolisers</u></em></p><p>Approximately 2.9&plusmn;1.5% of the population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60%. These findings have no implications for the posology of esomeprazole.</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>The metabolism of esomeprazole is not significantly changed in elderly subjects (71-80 years of age).</p><p>&nbsp;</p><p><em><u>Gender</u></em></p><p>Following a single dose of 40 mg esomeprazole the mean area under the plasma concentration-time curve is approximately 30% higher in females than in males. No gender difference is seen after repeated once-daily administration. These findings have no implications for the posology of esomeprazole.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired. The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the area under the plasma concentration-time curve of esomeprazole. Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction.Esomeprazole or its major metabolites do not show any tendency to accumulate with once-daily dosing.<em><u>Renal impairment</u></em></p><p>No studies have been performed in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.</p><p>&nbsp;</p><p><em><u>Paediatric population </u></em><em>Adolescents 12-18 years:</em></p><p>Following repeated dose administration of 20 mg and 40 mg esomeprazole, the total exposure (AUC) and the time to reach maximum plasma drug concentration (tmax) in 12 to 18 year-olds was similar to that in adults for both esomeprazole doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: Carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL-cell hyperplasia and carcinoids. These gastric effects in the rat are the result of sustained, pronounced hypergastrinaemia secondary to reduced production of gastric acid and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core </em>Sucrose Maize starch</p><p>Liquid glucose Hydroxypropylcellulose Povidone</p><p>Talc</p><p>Titanium dioxide (E171)</p><p>Methacrylic acid-ethyl acrylate copolymer (1:1) Glycerol monostearate</p><p>Propylene glycol Stearic acid Polysorbate 80 Simeticone</p><p>Microcrystalline cellulose Macrogol 6000 Crospovidone</p><p>Silica colloidal anhydrous Magnesium stearate</p><p>&nbsp;</p><p><em>Tablet coating</em></p><p>&nbsp;</p><p>&nbsp;&nbsp; Hypromellose &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Macrogol 6000</p><p>Titanium dioxide (E171) Talc</p><p>Iron oxide, red (E172)</p><p><em>Only for 20 mg</em>: Iron oxide, yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                HDPE bottles: 24 months
Shelf life after first opening: 6 months
Do not store above 25°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>HDPE bottles:</em></p><p>Storage conditions before opening of the HDPE bottle: Do not store above 25&deg;C.</p><p>For storage conditions after first opening of the HDPE bottle, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE bottles with PP cap and desiccant with 7, 14, 15, 28, 30, 56, 60, 90, 98, 100 and 250 gastro- resistant tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Administration via a stomach tube</u></p><p>&nbsp;</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put the tablet into an appropriate syringe and fill the syringe with approximately 25 ml water and approximately 5 ml air.</p><p>For some tubes, dispersion in 50 ml water is needed to prevent the pellets from clogging the tube.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediately shake the syringe for approximately 2 minutes to disperse the tablet.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the syringe with the tip up and check that the tip has not clogged.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attach the syringe to the tube whilst maintaining the above position.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake the syringe and position it with the tip pointing down. Immediately inject 5-10 ml into the tube. Invert the syringe after injection and shake it. Keep the syringe tip pointed upward as it will avoid clogging.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the syringe with the tip down and immediately inject another 5-10 ml into the tube. Repeat this procedure until the syringe is empty.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fill the syringe with 25 ml water and 5 ml air and repeat step 5 if necessary to wash down any sediment left in the syringe. Some tubes will require 50 ml water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz Farmaceutica S.A.,
Centro Empresarial Osa Mayor, 
Madrid, Spain

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                        05/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>